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Dear Sir, 
In a recently published case-control study Al-Rawi and Shahid have investigated the potential 
association between salivary lipid profile, lipid peroxidation and antioxidants, and the periodontal 
health status (using the Clinical Periodontal Sum Score or CPSS) of patients with acute coronary 
heart disease (CHD). Forty patients who had experienced CHD were matched for age, sex and 
residence to 40 patients without heart diseases. The lipid profile level, lipid peroxidation and 
antioxidant status were measured in the serum and saliva of all participants together with lactate 
dehydrogenase (LDH) and C-reactive protein. These parameters were then correlated with the 
periodontal status of the participants by a multiple linear regression. Salivary total cholesterol, 
triglycerides, low-density lipoprotein-cholesterol, very-low-density lipoprotein-cholesterol, 
malondialdehyde, uric acid, superoxide dismutase and LDH levels increased with the upper tertile 
of the CPSS, while salivary high-density lipoprotein-cholesterol decreased with the upper tertile of 
the CPSS. The authors concluded that periodontal status could be considered an independent risk 
factor for acute CHD.1 
   These results confirmed what is well known in the context of periodontal infections and CHD2 but 
could be expanded to other infections. Another example is that from Helicobacter pylori (H. 
pylori).3 H. pylori infection is a chronic one, acquired during childhood as a rule, and associated 
with low socio-economic class. The habitat of the bacterium is the stomach, where it is the major 
causal factor of gastritis, peptic ulcer, precancerous lesions, and a necessary but insufficient cause 
gastric cancer.4 Moreover, H. pylori has been involved in diverse aspects of several extragastric 
manifestations, including CHD. In this context, although currently available data do not prove in an 
unequivocal manner its role in the pathogenic mechanism of CHD, any potential relationship cannot 
be ruled out.3 A number of studies have reported conflicting results arising from several sources. 
From an epidemiological point of view, numerous discordances due to the lack of homogeneity 
emerged. There was a high degree of heterogeneity in the definition of CHD, the control groups 
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were biased, hence allowing for large variations in the adjustment of potential confounding factors. 
From a statistical point of view, often the sample size was small, with limitations and influence on 
the results due to potential α or  errors. From a clinical point of view, the main cause of 
heterogeneity stemmed from differences among heart diseases included in the studies: acute 
myocardial infarction, chronic CHD, angina, abnormalities in ECG, or total mortality due to any 
cardiovascular cause. Moreover, studies on the relationship between CHD and particular strains of 
the microorganism, characterized by a higher virulence have also given controversial results.3 A 
crucial question deals with possible pathogenic mechanisms through with the bacterium could be 
involved in CHD. H. pylori genomic material has been detected in the plaque only in sporadic 
occasions, in contrast to Chlamydia pneumoniae. Therefore, the hypothesis of an indirect pathway 
has been raised. Several mechanisms of damage have been proposed. Indeed, the long-term 
inflammation generated by H. pylori might raise cytokine levels in the bloodstream, and 
consequently, activate fibroblast and smooth muscle cell proliferation. It is improbable that the lipid 
profile or fibrinogen levels, as well as circulating markers of inflammation related to artery 
atherosclerosis, could be influenced by the bacterium. It has been shown that H. pylori binds von 
Willebrand factor and interacts with glycoprotein Ib to induce platelet aggregation.3 Hence, the 
speculation that the infection might induce platelet and immune activation mediated by cytokines, 
such as interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-α. Cytokines are intercellular 
signaling polypeptides, stimulators of the production of most acute-phase proteins. This step could 
play an important role in platelet adhesion and aggregation leading to plaque vulnerability and 
eliciting acute ischemic events. While atherosclerosis is an inflammatory disease in which immune 
mechanisms interact with metabolic factors to initiate, propagate, and activate lesions in the arterial 
tree, endothelial dysfunction is an early key event in the onset of acute coronary syndrome. Thus, 
the different features and presentations of CHD should be considered.2   
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Because CHD is the outcome of a multiplicity of factors, many of which with only a limited 
individual effect, complete understanding of causation is difficult. Moreover, since at least in the 
animal model a relationship between intestinal microbiota and myocardial infarction has been 
shown,3 and considering that the human bowel is the largest reservoir of microbes (it contains 
trillions of bacteria) in the body, with remarkable relevance for the human health,5 further studies 
should include the consideration of potential alterations of the physiologic intestinal microbiota.  
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